Clinical Trials Logo

Filter by:
NCT ID: NCT03408756 Not yet recruiting - Psoriasis Vulgaris Clinical Trials

Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis

Start date: April 1, 2018
Phase: Phase 4
Study type: Interventional

This study is a prospective, single blinded, randomized, pilot study to compare the effectiveness and safety profile of oral versus subcutaneous route of administration of methotrexate in management of patients with moderate to severe psoriasis. The recruited participants with moderate to severe psoriasis will be randomized into treatment arms. Randomization will be done using computer generated random number table. The participants in the first treatment arm will receive 0.3 mg/kg ( upto a maximum of 25 mg/week ) of weekly oral methotrexate for 12 weeks or achievement of PASI 90 whichever is earlier while the participants in second treatment arm will receive subcutaneous methotrexate at 0.3 mg/kg/week for the same duration. The participants will be followed at regular intervals and monitored adequately for hematological, hepatotoxic and other adverse effects both clinically and through laboratory investigations according to methotrexate consensus guidelines during the treatment period. PASI, percentage of body surface area (BSA) involvement and DLQI will be assessed at each follow up visit and at the end of 12 weeks. The treatment will be tapered at the rate of 5 mg/2 weeks and stopped after 12 weeks or achievement of PASI 90 whichever is earlier.. Follow ups will be done at every 2 weeks until treatment completion (12 weeks) and at every 4 weeks till 24 weeks after completion of treatment. The primary outcome measures will be achievement of PASI 90 (90 % reduction in psoriasis area severity score (PASI) compared to baseline).The secondary outcomes will be improvement in DLQI (dermatology life quality index), relapse rate and adverse events if any.

NCT ID: NCT03428672 Not yet recruiting - Clinical trials for Femoral Neck Fractures

Quantitative Analysis of Global Proteome in Bone Samples From Patients With Osteoporotic and Nonosteoporotic Fracture

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

RATIONALE: Collecting and storing bone samples from patients with osteoporotic and nonosteoporotic fracture to quantitatively analyze the differentially expressed proteins to further explain the relationship between bone iron content and bone mineral density (BMD). PURPOSE: This research study is looking at changes of iron content and differentially expressed proteins in bone samples from patients with osteoporotic and nonosteoporotic. fracture.

NCT ID: NCT03432468 Not yet recruiting - Hypertension Clinical Trials

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

This study compared the improvements of blood pressure levels, left ventricular hypertrophy, left ventricular diastolic function, vascular function and cognitive function between postmenopausal hypertensive women and age-matched hypertensive male patients through the evaluation of the effects of fully blocked AT1 receptor by valsartan. Additionally, the differences of the above indexes between the patients who were fully blocked AT1 receptor by valsartan and the patients who were treated with a single dose of valsartan treatment were assessed, so as to provide theory basis for clinical treatment of postmenopausal hypertensive women.

NCT ID: NCT03440502 Not yet recruiting - Spinal Anaesthesia Clinical Trials

Effect of Diabetes Mellitus on Spinal Block Criteria During Cesarean Section

Start date: April 1, 2018
Phase: N/A
Study type: Observational

The current study aimed at studying the effect of DM during pregnancy on the spinal block criteria during C.S. The primary end point of the trial is the incidence of complete failure of spinal block. Secondary endpoint is to determine the effect of DM on the other spinal block criteria as onset and duration of block, level of spinal block, rate of regression, hemodynamic changes, doses of inotropes and incidence of complications

NCT ID: NCT03448510 Not yet recruiting - Clinical trials for Lower Urinary Tract Symptoms

Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction

Start date: April 1, 2018
Phase: Phase 2
Study type: Interventional

Irreversible electroporation (IRE) is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane. It has been verified to be safe on the treatment of prostate, lung, liver and kidney masses. The present is a randomized, controlled trial, with a main purpose of looking into the safety and feasibility of irreversible electroporation for patients with benign prostatic obstruction.

NCT ID: NCT03449797 Not yet recruiting - Clinical trials for Primary Aldosteronism Due to Aldosterone Producing Adenoma

Rapid Cortisol Assay in Adrenal Vein Sampling

I-PADUA
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Background: Adrenal vein sampling (AVS) is the gold standard test for the subtyping of primary aldosteronism (PA). This procedure is hampered by unsuccessful bilateral cannulation of adrenal veins, which can occur in up to two thirds of the cases depending on the cutoff of the selectivity index used. The rapid intra-procedural cortisol assay (IRCA) can increase the rate of bilateral success of AVS. This can be proven using a randomized prospective study design approach. Aim: We will therefore evaluate if an IRCA-guided AVS strategy can increase the rate of selectivity and thus the success rate of adrenal vein catheterization. Methods: Consecutive patients with a biochemical diagnosis of PA, seeking surgical cure, will be randomized to undergo AVS according to an IRCA-sham or an IRCA-guided procedure. Experimental and endpoint will be the rate of bilaterally selective AVS studies as defined by a selective index cutoff > 2.00 value under baseline (unstimulated) conditions. With 100 patients submitted to AVS with a normal procedure and 100 patients undergoing AVS with IRCA, it has been estimated that the study has 82% power to detect a significant difference of 18% at a two-sided 0.05 significance level between arms. Expected results. Given this power we expect to the able to determine if IRCA is useful or not for improving the success rate of AVS. Given the current disastrous situation regarding the clinical use of AVS this will be a major accomplishment in the field of the subtyping of PA.

NCT ID: NCT03450551 Not yet recruiting - Clinical trials for Malocclusion, Angle Class II

Comparison of Efficacy of Three Orthodontic Appliances

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

To investigate each treatment modality in its "optimal" environment to avoid operator experience bias. Therefore we propose to operate out of three "specialist centres" with specific units providing one modality alone Which of the three orthodontic appliances does achieve best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.

NCT ID: NCT03451097 Not yet recruiting - Heart Failure Clinical Trials

Classification of Heart Failure in Children

Start date: April 1, 2018
Phase: N/A
Study type: Observational

Evaluation of Severity of Heart Failure in Children Attending Cardiology Unit, Assiut University Children Hospital

NCT ID: NCT03458065 Not yet recruiting - Clinical trials for ICD Shock Myocardial Injuries

T-ICD vs S-ICD Shocks: Myocardial Injuries

MYSTIC
Start date: April 1, 2018
Phase: N/A
Study type: Observational

Implantable cardioverter defibrillator (ICD) shocks are associated with a subsequent increased risk of death, and an elevation of cardiac enzymes has been measured after defibrillation testing (DFT). The aim of our study was to investigate the association between S-ICD vs T-ICD shocks and acute cardiac damage in humans, as evaluated by means of sensitive and highly specific circulating biomarkers

NCT ID: NCT03460223 Not yet recruiting - Renal Cirrhosis Clinical Trials

Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis

Start date: April 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. The potential for stem cells to treat kidney failure was recently confirmed. Particularly, mesenchymal stem cell (MSC) has been demonstrated to protect kidney function and alleviating renal injury in these patients. Therefore, the investigators propose a hypothesis that MSCs (MSC) can also improve the disease conditions of kidney fibrosis patients, particularly reducing the decompensated conditions in these patients.